药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
18-methyl-19-nortestosterone
Cilazaprilat
The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Cilazaprilat.
18-methyl-19-nortestosterone
Quinoline Yellow WS
The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Quinoline Yellow WS.
18-methyl-19-nortestosterone
Quinaprilat
The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Quinaprilat.
18-methyl-19-nortestosterone
Perindoprilat
The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Perindoprilat.
18-methyl-19-nortestosterone
Moexiprilat
The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Moexiprilat.
18-methyl-19-nortestosterone
Trandolaprilat
The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Trandolaprilat.
18-methyl-19-nortestosterone
Ramiprilat
The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Ramiprilat.
18-methyl-19-nortestosterone
Fosinoprilat
The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Fosinoprilat.
18-methyl-19-nortestosterone
Benazeprilat
The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Benazeprilat.
18-methyl-19-nortestosterone
Delapril
The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Delapril.
18-methyl-19-nortestosterone
Zofenopril
The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Zofenopril.
18-methyl-19-nortestosterone
Imidapril
The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Imidapril.
18-methyl-19-nortestosterone
Enalaprilat
The risk or severity of hyperkalemia can be increased when Potassium gluconate is combined with Enalaprilat.
Allylprodine
Satralizumab
The serum concentration of Dihydroergocristine can be decreased when it is combined with Satralizumab.
Allylprodine
Abametapir
The serum concentration of Dihydroergocristine can be increased when it is combined with Abametapir.
Allylprodine
Cenobamate
The serum concentration of Dihydroergocristine can be decreased when it is combined with Cenobamate.
Allylprodine
Testosterone undecanoate
Testosterone undecanoate may increase the hypertensive activities of Dihydroergocristine.
Allylprodine
Solriamfetol
The risk or severity of hypertension can be increased when Solriamfetol is combined with Dihydroergocristine.
Allylprodine
Esketamine
The risk or severity of hypertension can be increased when Esketamine is combined with Dihydroergocristine.
Allylprodine
2,5-Dimethoxy-4-ethylthioamphetamine
The therapeutic efficacy of Dihydroergocristine can be decreased when used in combination with 2,5-Dimethoxy-4-ethylthioamphetamine.